As per an earlier exchange filing dated 8 February 2025, the USFDA inspection at the Jigani unit concluded with six observations. Hikal had confirmed it would address each observation and submit its response within the stipulated timeframe.
In a subsequent filing dated 23 May 2025, the company informed that the inspection outcome had been classified as 'Official Action Indicated (OAI)' by the US FDA. Despite the regulatory classification, Hikal emphasized that it does not anticipate any impact on business continuity or the supply of existing products from the Jigani facility.
The company added that it remains fully committed to maintaining the highest standards of quality and compliance at all its facilities and is actively working to enhance regulatory adherence on an ongoing basis.
Hikal is engaged in the business of pharmaceuticals, crop protection, and specialty chemicals.
The company reported consolidated net loss of Rs 22.40 crore in Q1 FY26 as against net profit of Rs 5.10 crore reported in Q1 FY25. Revenue from operations fell 8% YoY to Rs 371.30 crore in the quarter ended 30 June 2025.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."